RBC Bioscience Corporation (TPEX:6848)
Taiwan · Delayed Price · Currency is TWD 20.60
+0.90 (4.57%)
Jun 12, 2026, 1:50 PM CST
RBC Bioscience Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 23.54 | 21.57 | 6.43 | 3.78 | 28.73 |
Depreciation & Amortization | 15.47 | 17.54 | 18.75 | 19.28 | 19.45 |
Other Amortization | 1.17 | 0.55 | 0.45 | 0.46 | 0.41 |
Loss (Gain) From Sale of Assets | - | -0 | 0.02 | -0.01 | 0.54 |
Asset Writedown & Restructuring Costs | - | - | - | - | 0.93 |
Provision & Write-off of Bad Debts | 0.08 | 0.42 | 0.11 | -0.1 | -0.37 |
Other Operating Activities | 0.51 | 3.43 | -7.15 | 1.3 | -28.74 |
Change in Accounts Receivable | -12.8 | 9.09 | 2.48 | -0.81 | 27.54 |
Change in Inventory | 5.27 | -8.34 | 2.78 | 4 | 9.59 |
Change in Accounts Payable | 0.3 | 8.05 | -6.99 | -13.04 | -65.31 |
Change in Unearned Revenue | 0.13 | 0.79 | 0.06 | -1.11 | 1.06 |
Change in Other Net Operating Assets | 6.84 | 2.83 | -3.73 | -7.14 | -19.11 |
Operating Cash Flow | 40.52 | 55.93 | 13.21 | 6.6 | -25.3 |
Operating Cash Flow Growth | -27.55% | 323.45% | 100.03% | - | - |
Capital Expenditures | -6.44 | -2.13 | -4.99 | -9.96 | -449.72 |
Sale of Property, Plant & Equipment | - | 0 | - | 0.01 | 0.01 |
Sale (Purchase) of Intangibles | -6.67 | -8.19 | -1.47 | -0.09 | -0.39 |
Other Investing Activities | -2.32 | 0.95 | 7.47 | 22.65 | 24.44 |
Investing Cash Flow | -15.43 | -9.37 | 1 | 12.61 | -425.67 |
Long-Term Debt Issued | - | 35 | 203.46 | - | 404.06 |
Total Debt Issued | - | 35 | 203.46 | - | 404.06 |
Short-Term Debt Repaid | -25 | -10 | -5 | -24.65 | -6.35 |
Long-Term Debt Repaid | -39.23 | -43.9 | -208.89 | -4.59 | -8.84 |
Total Debt Repaid | -64.23 | -53.9 | -213.89 | -29.24 | -15.19 |
Net Debt Issued (Repaid) | -64.23 | -18.9 | -10.43 | -29.24 | 388.87 |
Issuance of Common Stock | - | - | - | - | 50 |
Common Dividends Paid | -4.28 | -12.98 | -14.53 | -11.8 | -14.38 |
Other Financing Activities | - | - | - | 0.29 | - |
Financing Cash Flow | -68.52 | -31.88 | -24.96 | -40.75 | 424.49 |
Net Cash Flow | -43.42 | 14.68 | -10.75 | -21.54 | -26.48 |
Free Cash Flow | 34.08 | 53.8 | 8.21 | -3.36 | -475.02 |
Free Cash Flow Growth | -36.64% | 554.94% | - | - | - |
Free Cash Flow Margin | 15.51% | 26.21% | 4.76% | -1.93% | -189.12% |
Free Cash Flow Per Share | 2.37 | 3.75 | 0.57 | -0.23 | -35.11 |
Cash Interest Paid | 9.75 | 10.27 | 10.08 | 7.41 | 5.94 |
Cash Income Tax Paid | 5.69 | 2 | 8.55 | 0 | 36.35 |
Levered Free Cash Flow | 16.8 | 38.36 | 2.95 | 19.92 | -460.85 |
Unlevered Free Cash Flow | 22.86 | 44.81 | 9.2 | 24.66 | -456.89 |
Change in Working Capital | -0.25 | 12.43 | -5.4 | -18.11 | -46.24 |